Evidence map›Paper›PMID 30912402›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2019

Association of Protein Expression and Methylation of DAPK1 with Clinicopathological Features in Invasive Ductal Carcinoma Patients from Kashmir

Asia Asiaf, Shiekh Tanveer Ahmad, Ajaz Ahmad Malik, Shiekh Aejaz Aziz, Mohammad Afzal Zargar

Open access · goldAbstract read
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Epigenetic Silencing ofIndian journal of clinical biochemistry : IJCB · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Asia AsiafDepartment of Biotechnology, School of Life Sciences, Central University of Kashmir, Srinagar, J and K, India. Email: mazargar65@gmail.com
Shiekh Tanveer AhmadClarke H. Smith Brain Tumour Centre, Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary, Calgary Alberta, Canada.
Ajaz Ahmad MalikDepartment of General Surgery, Sher-I-Kashmir Institute of Medical Sciences, Soura, Srinagar, J and K, India.
Shiekh Aejaz AzizDepartmet of Medical Oncology, Sher-I-Kashmir, Institute of Medical Sciences, Soura Srinagar, J and K, India.
Mohammad Afzal ZargarDepartment of Biotechnology, School of Life Sciences, Central University of Kashmir, Srinagar, J and K, India. Email: mazargar65@gmail.com
Central University of Kashmir · INUniversity of Kashmir · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aims: Death-associated protein kinase-1 (DAPK1) is a pro-apoptotic Ser/Thr kinase that participates in cell apoptosis and tumor suppression. DAPK1 is frequently lost in many different tumor types including breast cancer. The aim of this study was to evaluate the promoter methylation status of DAPK1 and a possible correlation with the expression of DAPK1 and standard clinicopathological features in invasive ductal breast carcinoma patients (IDC). Methods: Methylation Specific PCR (MSP) was carried out to investigate the promoter methylation status of DAPK1 from 128 breast cancer patients. The effect of promoter methylation on protein expression was evaluated by immunohistochemistry (n=128) and western blotting (n=56). Results: We found significant difference in DAPK1 promoter methylation frequency among breast tumors when compared with the corresponding normal tissues. Hypermethylation of DAPK1 is significantly correlated with the loss of DAPK1 protein expression (P < .001, rs= -0.361). The loss of DAPK1 protein was significantly associated with estrogen receptor (ER) negativity (p= 0.003), triple negative breast cancer (TNB) (p= 0.024) and advanced tumor stages (P = 0.001). Moreover, age at diagnosis (p= 0.041), tumor stage (p= 0.034), ER negativity (p= 0.004) and TNB cancers (p=0.003) correlated significantly with the hypermethylation of the DAPK1 promoter. Coclusion: This study indicates that DAPK1 is methylated in IDC and promoter hypermethylation could be attributed to silencing of DAPK1 gene expression in breast cancer. Thus, we consider DAPK1 inactivation by promoter hypermethylation likely plays a role in the development and progression of breast cancer.

Indexed as

DNA MethylationGene Expression Regulation, NeoplasticAdultAgedAged, 80 and overBiomarkers, TumorBreast NeoplasmsCarcinoma, Ductal, BreastDeath-Associated Protein KinasesFemaleFollow-Up StudiesHumansMiddle AgedNeoplasm StagingPromoter Regions, GeneticBiomarkers, TumorDAPK1 protein, humanDeath-Associated Protein KinasesBreast cancerDAPK1hypermethylationimmunohistochemistryMSP

Identifiers

PMID30912402
PMCPMC6825784
OpenAlexW2912699106

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.